Zurich-Schlieren, Switzerland (Press Release) – Molecular Partners AG (SIX:MOLN), a clin­i­cal-stage bio­tech com­pany pioneering the use of DARPin® thera­peutics to treat serious dis­eases, announces the receipt of Orphan Drug Desig­na­tion by the US Food and Drug Admin­istra­tion (FDA) for its novel thera­peutic, MP0250, for the treat­ment of multiple myeloma.

MP0250 is a first-in-class, tri-specific multi-DARPin® drug can­di­date neutralizing VEGF-A and HGF and is binding to human serum albumin to in­crease plasma half-life. The unique mech­a­nism of action of MP0250 rep­re­sents a new ap­proach to targeting the tumor microenvironment and in­crease patients' re­sponse­s to …